ECAP闭环与开环脊髓电刺激治疗慢性疼痛:EVOKE盲法随机试验36个月结果
EVOKE多中心盲法随机对照试验比较ECAP控制的闭环脊髓电刺激(CL-SCS)与固定输出开环刺激(OL-SCS)治疗慢性难治性腰腿痛,随访36个月。CL-SCS组达到背腿痛整体强度降低≥50%的比例为77.6%,OL-SCS组为49.3%(差异28.4%,95%CI 12.8%–43.9%,p<0.001);CL-SCS组整体治疗应答率更高(44.8% vs 28.4%),神经激活更优,两组不良事件无差异。
要点
- 36个月时CL-SCS组疼痛缓解≥50%比例显著高于OL-SCS组(77.6% vs 49.3%)。
- CL-SCS组整体治疗应答率更高(44.8% vs 28.4%),神经激活更优。
- 两组不良事件无差异,CL-SCS组无因疗效丧失而移除装置。
核心结论
- ECAP控制的闭环SCS在36个月时提供持续、持久的疼痛缓解和更优的整体治疗应答。
- 闭环SCS较开环SCS观察到更大的神经激活和更高的治疗递送准确性。
研究设计与样本
- EVOKE研究为多中心、参与者盲法、研究者盲法、结局评估者盲法的随机对照平行臂临床试验。
- 纳入慢性难治性腰腿痛且保守治疗无效的患者,2017年1月至2018年2月入组,随访至36个月。
- 主要结局为整体背部和腿部疼痛强度降低至少50%。
主要发现
- 36个月时CL-SCS组77.6%与OL-SCS组49.3%的患者报告整体背腿痛降低≥50%(差异28.4%,95%CI 12.8%–43.9%,p<0.001)。
- CL-SCS组49.3%与OL-SCS组31.3%的患者报告降低≥80%(差异17.9%,95%CI 1.6%–34.2%,p=0.032)。
- 36个月时两组在其他患者报告结局均较基线有临床意义改善,CL-SCS组改善程度更大。
- 36个月随访时CL-SCS组44.8%与OL-SCS组28.4%的患者为整体治疗应答者,CL-SCS组累积应答评分更高。
- 两组不良事件无差异,CL-SCS组无因疗效丧失而移除装置。
关键数值与推荐
- 主要结局应答定义为整体背部和腿部疼痛强度降低至少50%。
- 整体治疗应答为包含疼痛强度、身体和情绪功能、睡眠及健康相关生活质量的复合结局。
临床怎么用
- 对于慢性难治性腰腿痛患者,ECAP控制的闭环SCS可能提供优于固定输出开环SCS的长期疼痛缓解和整体治疗应答。
- 闭环SCS可考虑作为需要持续、持久疼痛改善患者的治疗选择。
局限性
- 原文摘要未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The evidence for spinal cord stimulation (SCS) has been criticized for the absence of blinded, parallel randomized controlled trials (RCTs) and limited evaluations of the long-term effects of SCS in RCTs. The aim of this study was to determine whether evoked compound action potential (ECAP)-controlled, closed-loop SCS (CL-SCS) is associated with better outcomes when compared with fixed-output, open-loop SCS (OL-SCS) 36 months following implant. METHODS: The EVOKE study was a multicenter, participant-blinded, investigator-blinded, and outcome assessor-blinded, randomized, controlled, parallel-arm clinical trial that compared ECAP-controlled CL-SCS with fixed-output OL-SCS. Participants with chronic, intractable back and leg pain refractory to conservative therapy were enrolled between January 2017 and February 2018, with follow-up through 36 months. The primary outcome was a reduction of at least 50% in overall back and leg pain. Holistic treatment response, a composite outcome including pain intensity, physical and emotional functioning, sleep, and health-related quality of life, and objective neural activation was also assessed. RESULTS: At 36 months, more CL-SCS than OL-SCS participants reported ≥50% reduction (CL-SCS=77.6%, OL-SCS=49.3%; difference: 28.4%, 95% CI 12.8% to 43.9%, p<0.001) and ≥80% reduction (CL-SCS=49.3%, OL-SCS=31.3%; difference: 17.9, 95% CI 1.6% to 34.2%, p=0.032) in overall back and leg pain intensity. Clinically meaningful improvements from baseline were observed at 36 months in both CL-SCS and OL-SCS groups in all other patient-reported outcomes with greater levels of improvement with CL-SCS. A greater proportion of patients with CL-SCS were holistic treatment responders at 36-month follow-up (44.8% vs 28.4%), with a greater cumulative responder score for CL-SCS patients. Greater neural activation and accuracy were observed with CL-SCS. There were no differences between CL-SCS and OL-SCS groups in adverse events. No explants due to loss of efficacy were observed in the CL-SCS group. CONCLUSION: This long-term evaluation with objective measurement of SCS therapy demonstrated that ECAP-controlled CL-SCS resulted in sustained, durable pain relief and superior holistic treatment response through 36 months. Greater neural activation and increased accuracy of therapy delivery were observed with ECAP-controlled CL-SCS than OL-SCS. TRIAL REGISTRATION NUMBER: NCT02924129.
引用
- Mekhail NA, Levy RM, Deer TR, et al. ECAP-controlled closed-loop versus open-loop SCS for the treatment of chronic pain: 36-month results of the EVOKE blinded randomized clinical trial. Reg Anesth Pain Med. 2024. PMID: 37640452. doi:10.1136/rapm-2023-104751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。